Related Experiment Video
Updated: Jan 29, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
18.3K
FKB327: An Adalimumab Biosimilar
1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
Summary
FKB327 (Hulio) is a biosimilar to adalimumab, demonstrating equivalent efficacy and safety in rheumatoid arthritis patients. Switching from adalimumab to FKB327 showed no negative impact on treatment outcomes.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Adalimumab is a key biologic therapy for rheumatoid arthritis.
- Biosimilars offer potential for cost-effective treatment options.
- FKB327 (Hulio) is an adalimumab biosimilar approved in the EU.
Purpose of the Study:
- To evaluate the efficacy, safety, tolerability, and immunogenicity of FKB327 compared to reference adalimumab.
- To assess the impact of switching from reference adalimumab to FKB327.
Main Methods:
- Pharmacokinetic equivalence study in healthy volunteers and RA patients.
- Clinical trial comparing FKB327 and reference adalimumab in moderate-to-severe RA patients.
- Assessment of safety, tolerability, and immunogenicity profiles.
Main Results:
- FKB327 showed similar physicochemical and pharmacodynamic properties to adalimumab.
- Pharmacokinetic equivalence was demonstrated in healthy volunteers and RA patients.
- Equivalent clinical efficacy, safety, tolerability, and immunogenicity were observed.
- Switching from adalimumab to FKB327 did not affect efficacy, safety, or immunogenicity.
Conclusions:
- FKB327 is a clinically effective and safe biosimilar to adalimumab for rheumatoid arthritis.
- Switching to FKB327 is a viable option for patients on adalimumab therapy.
- FKB327 provides a comparable treatment option with potential healthcare economic benefits.
